Bumps In The Road As US FDA Tries To Catch Up From Shutdown
Executive Summary
The recently ended record-setting US government shutdown is not anticipated to have a long-term impact on US FDA device review times. But agency reviewers will face more 510(k) review deadline pressures than usual and may have limited availability for pre-submission meetings in the short term, one expert suggests.
You may also be interested in...
Congress Agrees To Keep FDA, Other Agencies Running At Current Funding Level Through Mid-December
The US Congress this week agreed to keep the FDA and other government agencies funded at fiscal-year 2019 levels, extending the continuing resolution another four weeks until 20 December.
US FDA Inspection Goals Reduced After Shutdown; Review Dates Look Safe
Commissioner Scott Gottlieb tells Congress FDA won’t meet all its planned inspection goals after a month-long partial government shutdown, but he does not expect a noticeable impact on product reviews. Longer-term impacts will depend on morale: hiring and retention are focal points.
Trump Signs 2019 US Federal Funding Bill, Stopping Another FDA Shutdown; CDRH Sees $69M Boost
US FDA’s device center gained a total of $471.4m in budget authority, plus more than $200m that Congress authorized in user-fee funding for the current fiscal year, in a 2019 federal agency spending package signed into law Feb. 15 by the president that prevented a second agency shutdown. The $471.4m budget is roughly $69m more than was given to CDRH for FY 2018.